Isolation, Biosynthesis, and Biological Activity of Polycyclic Xanthones From Actinomycetes

Natural products from actinomycetes serve as a crucial source of clinical pharmaceuticals, especially antibiotics and anticancer agents. Among them, polycyclic xanthones belong to a growing group of highly oxygenated aromatic polyketides with a xanthone-containing angular hexacyclic framework. These...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 13; p. 922089
Main Authors Yu, Hui-Qing, Li, Gang, Lou, Hong-Xiang
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 13.07.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Natural products from actinomycetes serve as a crucial source of clinical pharmaceuticals, especially antibiotics and anticancer agents. Among them, polycyclic xanthones belong to a growing group of highly oxygenated aromatic polyketides with a xanthone-containing angular hexacyclic framework. These biosynthetically unique small molecules are of great interest due to their wide spectrum of biological activities, especially the remarkable antibacterial activity against gram-positive bacteria and the significant antineoplastic effects toward various cancer cells at nanomolar concentrations. Their complex structures and significant bioactivities have aroused considerable attention in the chemical and biological communities in recent decades. This review covers the isolation, the biosynthesis, and the biological studies toward these structurally complex and biologically active molecules.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Microbiotechnology, a section of the journal Frontiers in Microbiology
Edited by: Satish Sreedharamurthy, University of Mysore, India
Reviewed by: Agustinus R. Uria, Hokkaido University, Japan; Karthik Loganathan, Salem Microbes Pvt Ltd., India
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2022.922089